B cell depletion in diffuse progressive systemic sclerosis safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.docVIP

下载本文档

5
0
约3.82万字
约 10页
2017-05-15 发布于上海
举报

B cell depletion in diffuse progressive systemic sclerosis safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.doc

B cell depletion in diffuse progressive systemic sclerosis safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

Boselloetal.ArthritisResearchTherapy2010,12:R54 /content/12/2/R54 RESEARCH ARTICLE OpenAccess Bcelldepletionindiffuseprogressivesystemic sclerosis:safety,skinscoremodificationandIL-6 modulationinanuptothirty-sixmonths follow-upopen-labeltrial SilviaBosello1,MariaDeSantis1,GinaLama2,CristinaSpanò2,CristianaAngelucci2,BarbaraTolusso1,GigliolaSica2, GianfrancoFerraccioli1* Abstract Introduction:Anover-expressionofCD19hasbeenshowninBcellsofsystemicsclerosis(SSc)andBcellsare thoughttocontributetotheinductionofskinfibrosisinthetightskinmousemodel.Theaimwastodefinethe outcomeonsafetyandthechangein

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

B cell depletion in diffuse progressive systemic sclerosis safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.docVIP